Literature DB >> 10511289

HDL metabolism in hypertriglyceridemic states: an overview.

B Lamarche1, S Rashid, G F Lewis.   

Abstract

Reduced plasma high-density lipoprotein (HDL) cholesterol levels have been recognized as a highly significant independent risk factor for atherosclerotic cardiovascular disease. HDL levels are also inversely related to plasma triglyceride levels and there is a dynamic interaction between HDL and triglyceride (TG) rich lipoproteins in vivo. The mechanisms underlying the lowering of HDL in hypertriglyceridemic states have not been fully elucidated, but there is evidence to suggest that triglyceride enrichment of HDL, a common metabolic consequence of hypertriglyceridemia, may play an important role in this process. There is accumulating evidence to suggest that the primary mechanisms leading to reduced plasma HDL cholesterol levels and HDL particle number in hypertriglyceridemic states may be due to any one or a combination of the following possibilities: (1) small HDL particles, which are the product of the intravascular lipolysis of triglyceride-enriched HDL, may be cleared more rapidly from the circulation, (2) triglyceride-enriched HDL may be intrinsically more unstable in the circulation, with apo A-I loosely bound, (3) the lipolytic process itself of triglyceride-enriched HDL may lower HDL particle number by causing apo A-I to be shed from the HDL particles and cleared from the circulation, (4) a dysfunctional lipoprotein lipase or reduced LPL activity may contribute to the lowering of HDL levels by reducing the availability of surface constituents of triglyceride-rich lipoproteins that are necessary for the formation of nascent HDL particles. This review summarizes the evidence that triglyceride-enrichment of HDL is an important factor determining the rate at which HDL is catabolized, a mechanism which could explain, at least in part, the reduced plasma HDL cholesterol levels and particle number frequently observed in hypertriglyceridemic states.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511289     DOI: 10.1016/s0009-8981(99)00098-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  34 in total

1.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom
Journal:  Lung Cancer       Date:  2008-03-14       Impact factor: 5.705

2.  Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study.

Authors:  Hiroshi Yoshida; Hidekatsu Yanai; Toru Shoda; Nobuyuki Furutani; Noriko Sato; Norio Tada
Journal:  Curr Ther Res Clin Exp       Date:  2005-11

Review 3.  HDL dysfunction in diabetes: causes and possible treatments.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

Review 4.  Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights.

Authors:  Madhurima Das; Olga Gursky
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

5.  Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects.

Authors:  Michael Miller; Patricia Langenberg; Stephen Havas
Journal:  Int J Cardiol       Date:  2006-10-18       Impact factor: 4.164

Review 6.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

7.  In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment.

Authors:  Ana C Lo Prete; Clederson H Dina; Carolina H Azevedo; Camila G Puk; Neuza H M Lopes; Whady A Hueb; Raul Cavalcante Maranhão
Journal:  Lipids       Date:  2009-09-16       Impact factor: 1.880

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

Review 9.  Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Authors:  Jing Pang; Dick C Chan; Gerald F Watts
Journal:  World J Diabetes       Date:  2014-04-15

10.  Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

Authors:  Theodore W K Ng; Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-10-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.